Background: Significant shortcomings have been displayed in conventional
chemotherapeutics delivery which possesses some genuine side effects including harm
of the immunity and different organs with quickly multiplying cells because of nonparticular
focus on the absence of dissolvability and powerlessness to enter the tumor
core bringing about debilitated treatment with diminished dosage and with low survival
rate. Rapid development has adapted nanocarriers as distinct therapeutics which can directly
access the tumor cells specifically with expanded medication limitation and cell
take-up for cancer treatment.
Methodology: This review focuses on core objective of drug targeting to the cancerous
cells by demonstrating the advantages of the young medical field, “nanocarriers” including
liposomes, polymer based nanoparticles, metal based nanoparticles, dendrimers, protein
linked systems, co-polymers and fullerenes, which have been proven remarkably
promising in enhancing drug distribution and bioavailability, increasing half life and
achieving targeted drug delivery, thus reducing toxicity.
Conclusion: Here we provide an update on the recent clinical trials in nanocarrier based
therapy of colon rectal cancer, food and drug administration (FDA) approved
nanomedicines for cancer and those in nanoplatforms which have reached an advanced
stage of clinical development.